Antibody Market, By Product Type (Monoclonal Antibodies, Polyclonal Antibodies, Antibody-drug Complexes), By End-User (Hospitals, Long-term Care Facilities, Research Institutes), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Antibody Market was valued at US$ 242.8Billion in 2024 and is projected to grow at a CAGR of 11.80% to reach US$ 743.6Billion by 2034.

[PDF] Antibodies are proteins that protect the body when an unwanted substance enters the body. It is produced by the immune system; antibodies bind to these unwanted substances in order to eliminate them from an individual’s system. Antibodies are produced by specialized white blood cells called B lymphocytes (or B cells). They are grouped into five classes mainly as IgG, IgM, IgA, IgD, and IgE.

Rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and others have given rise in demand for biologics which are anticipated to become key factors in the growth of the Antibody Market. More patients and doctors are becoming aware of these therapies, more antibody therapies are being used for targeted treatments, which has also become the factor for fueling in the growth of the target market. Additionally, the growth of COVID-19 pandemic has also become the major contribution in Antibody Market growth.

 

Increased investment in medical and health research and development is expected to fuel the growth of the Antibodies market. Antibodies and reagents are essential tools in the study of biological mechanisms or the origins of disease through meticulous experimentation, observation, laboratory work, analysis, and testing. The increase in investment in healthcare research and development will lead to increased use of research antibodies and will eventually propel the growth of Antibody Market.

For instance, in December 2019, according to the report from Research America, total U.S. investment in medical and health research and development (R&D) grew by 6.4% from 2017 to 2018, reaching up to $194.2 billion. The growth rate of investments in medical and health R&D outperformed the growth rate of total health spending for the third year in a row. The health industry invested $129.5 billion (66.7%), followed by $43 billion (22.2%) from federal agencies and $21.7 billion (11.2%) from foundations, state and local governments, academic research institutions, and voluntary health associations.

Furthermore, in October 2020, Centivax Inc., a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services announced a licensing agreement with Thermo Fisher Scientific, an American supplier of scientific instrumentation, reagents and consumables, and software services for the anti-COVID-19 antibodies. Thermo Fisher has developed and evaluated several variants of Centivax's highly specific and effective therapeutic antibody candidates against COVID-19 for the use in research, which includes flow cytometry, histopathology, in vitro and in vivo neutralization, Luminex and ELISA applications. The products are commercially available to academic and industry research laboratories.

Increasing prevalence of neurodegenerative diseases to fuel market growth

Antibodies are now one of the most important research tools for projects examining the functions of various proteins in cells. The rising prevalence of neurodegenerative diseases such as Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fueling the growth of Antibody Market. Additionally, the rise in the geriatric population and the lack of effective treatments for chronic diseases have increased the demand for antibodies which in turn boost the growth of Antibody Market.

For instance, according to Centers for Disease Control and Prevention (CDC), when the mortality from presenile dementia (PSD), Alzheimer's disease (AD), Parkinson's disease (PD), and motor neuron disease (MND) was examined for 27 states, a total of 130,420 deaths from the four neurodegenerative diseases were recorded during the study period. Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. The population prevalence of PD increases from about 1% at age 60 to 4% by the age of 80. The increasing prevalence of Alzheimer’s disease was recorded 5 million people in the year 2014 which is about 1.6% of the U.S. population. The values are projected to grow about 13.9 million at the year in 2060, which is nearly about 3.3 percent of the population.

Restrains:

Antibody production requires in-depth expertise and thorough research, both of which comes with substantial financial costs and time constraints which in turn limiting the target market growth. Large bioreactors, filtration systems, medium, and buffers for upstream/downstream processing and purification are additional technologies needed for antibody synthesis. As a result, the average price of producing antibodies continues to rise in accordance with the extra services needed, which is also restraining the growth of Antibody Market. The antigen against which the site-specific antibody must be developed, as well as the antibodies' specificity and reproducibility, must be taken into account. As a result, the price of antibodies restrains the expansion of Antibody Market.

 

Antibody Market is segmented based on Product Type, End-Users and Region.

Product Type Insight

On the basis of Product Type, Antibody Market is segmented into Monoclonal Antibodies, Polyclonal Antibodies, Antibody-drug Complexes.  Monoclonal Antibodies segment is expected to dominate the target market growth due to the rising approval rates and increasing cases of rheumatoid arthritis, psoriasis, asthma in the geriatric population. The rising demand for effective treatment of the chronic diseases is anticipated to fuel the growth of this segment.

End-Users Insights

On the basis of End-Users, Antibody Market is segmented into Long-term Care Facilities, Research Institutes. The Hospitals segment is expected to dominate the target market growth due to the increasing adoption of the antibodies for cancer treatment at hospitals. Rising healthcare expenditure across the world, increasing patient awareness levels, increasing government support and availability of advanced hospital infrastructure in developed countries are the factors driving the growth of this segment.

Regional Insights:

On the basis of region, the Antibody Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research prospects. Additionally, increasing government expenditure for cancer research and the presence of key companies are anticipated to increase demand for antibodies in the region.

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Product Type – Monoclonal Antibodies, Polyclonal Antibodies, Antibody-drug Complexes By End-Users - Hospitals, Long-term Care Facilities, Research Institutes
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Antibody Market report based on Product Type, End-Users and Region:

Antibody Market, By Product Type:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Antibody-drug Complexes

Antibody Market, By End-Users:

• Hospitals
• Long-term Care Facilities
• Research Institutes

Antibody Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Antibody Market includes, Novartis AG, Roche Holding AG, Johnson & Johnson, Takeda Pharmaceutical Company, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi SA, and Eli Lilly and Co.

Recent Development:

The New Launched Product News,

• In November 2023, Lonza announced the launch of new cell line, GS Effex,  intended for the development of therapeutic antibodies with enhanced potency. Derived from the company’s GS Xceed cell line, GS Effex meets the development needs for more sophisticated therapeutic antibodies. The new cell line combines the characteristics of good cell growth with the ability to produce therapeutic antibodies with increased potency.
• In December 2023, Partillion Bioscience Corporation ("Partillion"), a life science tools company, announced the commercial availability of two new products to accelerate antibody discovery from mouse antibody-secreting cells. These Antibody Discovery Kits provide reagents that streamline workflows to select plasma cells or hybridoma cells secreting antigen-specific antibodies for downstream sequencing.

• Novartis AG *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Roche Holding AG
• Johnson & Johnson
• Takeda Pharmaceutical Company
• Amgen Inc.
• Biogen Inc.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Sanofi SA
• Eli Lilly and Co.

“*” marked represents similar segmentation in other categories in the respective section

to 2032.

 

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Product Type
     • Market Snippet, By End-Users
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Antibody Market, By Product Type
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Monoclonal Antibodies
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Polyclonal Antibodies
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Antibody-drug Complexes
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032

 

1. Antibody Market, By End-Users, 2022 – 2032, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Hospitals
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Long-term Care Facilities
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Research Institutes
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
2. Antibody Market, By Region, 2022 – 2032, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

• • Latin America
    • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
• • • • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Product Type, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032

1. • • • GCC
       • Israel
       • South Africa
       • Rest of Middle East
2. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
3. Company Profiles 

• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche Holding AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Takeda Pharmaceutical Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Amgen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biogen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AbbVie Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sanofi SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly and Co.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact